Article
Vancouver, British Columbia-An $855 million deal will unite verteporfin (Visudyne) developer QLT Inc. and Atrix Laboratories Inc. to build QLT's business and accelerate strategic initiatives.
Floppy iris syndrome risk: Study finds women more susceptible, key drugs identified
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Iantrek announces positive 2-year results from clinical study of its bio-interventional platform for uveoscleral outflow enhancement
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Ocugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200
Formosa Pharmaceuticals enters into licensing agreement with Cipla for commercialization of APP13007 across 11 countries